Julien Adam
About
Julien Adam is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Immunology.
According to data from OpenAlex, Julien Adam has authored 171 papers receiving a total of 4.7k indexed citations (citations by other indexed papers that have themselves been cited), including 121 papers in Oncology, 74 papers in Pulmonary and Respiratory Medicine and 33 papers in Immunology. Recurrent topics in Julien Adam's work include Cancer Immunotherapy and Biomarkers (72 papers), Lung Cancer Treatments and Mutations (37 papers) and Cancer Genomics and Diagnostics (22 papers). Julien Adam is often cited by papers focused on Cancer Immunotherapy and Biomarkers (72 papers), Lung Cancer Treatments and Mutations (37 papers) and Cancer Genomics and Diagnostics (22 papers). Julien Adam collaborates with scholars based in France, United States and Spain. Julien Adam's co-authors include Benjamin Besse, Vincent de Montpréville, Aïcha Goubar, David Planchard, Fathia Mami‐Chouaib, Pierre Validire, Aurélie Durgeau, Guillaume Meurice, Axel Le Cesne and Fabrice André and has published in prestigious journals such as Nature Communications, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.
In The Last Decade
Julien Adam
159 papers receiving 4.6k citations
Hit Papers
Peers — A (Enhanced Table)
Peers by citation overlap · career bar shows stage (early→late) cites · hero ref
| Name | h | Career | Trend | Papers | Cites | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| Julien Adam France | 35 | 3.0k | 1.6k | 1.4k | 1.1k | 954 | 171 | 4.7k | ||
| Jennifer H. Yearley United States | 24 | 3.7k 1.3× | 1.4k 0.8× | 2.6k 1.9× | 1.1k 1.0× | 664 0.7× | 56 | 5.7k | ||
| Erminia Massarelli United States | 32 | 3.2k 1.1× | 2.1k 1.3× | 729 0.5× | 1.2k 1.1× | 648 0.7× | 140 | 4.6k | ||
| Salvador Martín‐Algarra Spain | 30 | 2.2k 0.7× | 928 0.6× | 1.1k 0.8× | 1.3k 1.2× | 722 0.8× | 137 | 3.8k | ||
| Thomas Olencki United States | 30 | 2.0k 0.7× | 1.8k 1.1× | 886 0.6× | 1.6k 1.4× | 797 0.8× | 122 | 4.0k | ||
| Nicolás A. Giraldo France | 21 | 3.6k 1.2× | 2.2k 1.4× | 2.4k 1.7× | 2.0k 1.8× | 1.5k 1.5× | 33 | 6.1k | ||
| Helen K. Angell United Kingdom | 22 | 4.0k 1.4× | 1.9k 1.2× | 2.7k 2.0× | 2.1k 1.9× | 1.4k 1.5× | 40 | 6.5k | ||
| Takeshi Kuwata Japan | 43 | 2.9k 1.0× | 1.8k 1.1× | 1.4k 1.0× | 1.9k 1.7× | 901 0.9× | 198 | 5.9k | ||
| Gene Grant Finley United States | 19 | 3.3k 1.1× | 2.2k 1.3× | 690 0.5× | 961 0.9× | 466 0.5× | 70 | 4.4k | ||
| Peter Langmuir United States | 30 | 1.8k 0.6× | 1.6k 1.0× | 888 0.6× | 1.3k 1.2× | 507 0.5× | 56 | 4.7k | ||
| Ashley Cimino‐Mathews United States | 37 | 2.2k 0.7× | 907 0.6× | 784 0.6× | 924 0.8× | 922 1.0× | 122 | 3.8k |
Countries citing papers authored by Julien Adam
Since
Specialization
Citations
This map shows the geographic impact of Julien Adam's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Julien Adam with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Julien Adam more than expected).
Fields of papers citing papers by Julien Adam
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Julien Adam. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Julien Adam. The network helps show where Julien Adam may publish in the future.
Co-authorship network of co-authors of Julien Adam
This figure shows the co-authorship network connecting the top 25 collaborators of Julien Adam. A scholar is included among the top collaborators of Julien Adam based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Julien Adam. Julien Adam is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Auclin, Édouard, Julien Adam, Sébastien Mella, et al.. (2025). Different tumour-resident memory T-cell subsets regulate responses to anti-PD-1 and anti-CTLA-4 cancer immunotherapies. Nature Communications. 16(1). 5588–5588.
2.
Lefebvre, Anne‐Marie, Julien Adam, Céline Nicolazzi, et al.. (2023). The search for therapeutic targets in lung cancer: Preclinical and human studies of carcinoembryonic antigen-related cell adhesion molecule 5 expression and its associated molecular landscape. Lung Cancer. 184. 107356–107356.
3.
Iseas, Soledad, Guillermo Méndez, Marcela Carballido, et al.. (2023). Prognostic Factors of Long-Term Outcomes after Primary Chemo-Radiotherapy in Non-Metastatic Anal Squamous Cell Carcinoma: An International Bicentric Cohort. Biomedicines. 11(3). 791–791.
4.
Adam, Julien, Laurence Lamant, Maxime Battistella, et al.. (2022). Harmonization of programmed death‐ligand 1 immunohistochemistry and mRNA expression scoring in metastatic melanoma: a multicentre analysis. Histopathology. 80(7). 1091–1101.
5.
Kossaï, Myriam, C. Radulescu, Julien Adam, et al.. (2021). Plasmacytoid urothelial carcinoma (UC) are luminal tumors with similar CD8+ Tcell density and PD-L1 protein expression on immune cells as compared to conventional UC. Urologic Oncology Seminars and Original Investigations. 40(1). 12.e1–12.e11.
6.
Nicolazzi, Céline, Anne Caron, Alexia Tellier, et al.. (2020). An Antibody–Drug Conjugate Targeting MUC1-Associated Carbohydrate CA6 Shows Promising Antitumor Activities. Molecular Cancer Therapeutics. 19(8). 1660–1669.
7.
Boilève, Alice, Armelle Dufresne, Ali N. Chamseddine, et al.. (2020). Outcomes of patients with metastatic gastrointestinal stromal tumors (GIST) treated with multi-kinase inhibitors other than imatinib as first-line treatment. ESMO Open. 5(6). e001082–e001082.
8.
Rouanne, Mathieu, C. Radulescu, Julien Adam, & Yves Allory. (2020). PD-L1 testing in urothelial bladder cancer: essentials of clinical practice. World Journal of Urology. 39(5). 1345–1355.
9.
Tériitéhau, C., Julien Adam, Jimmy Kyaw Tun, et al.. (2020). Lung microwave ablation – an in vivo swine tumor model experiment to evaluate ablation zones. International Journal of Hyperthermia. 37(1). 879–886.
10.
Bachelot, Thomas, Thomas Filleron, Florence Dalenc, et al.. (2020). 128O PDL1/CD274 gain/amplification as a predictive marker of checkpoint blockade inhibitor efficacy in metastatic breast cancer: Exploratory analysis of the SAFIR02-IMMUNO randomized phase II trial. Annals of Oncology. 31. S58–S59.
11.
Raingeaud, Joël, Joel Paulo Russomano Veiga, Laëtitia Marisa, et al.. (2019). ROCK 2 inhibition triggers the collective invasion of colorectal adenocarcinomas. The EMBO Journal. 38(14). e99299–e99299.
12.
Adam, Julien, Véronique Hofman, Audrey Mansuet‐Lupo, et al.. (2019). P2.09-17 Real-World Concordance Across Pathologists for PD-L1 Scoring in Non-Small Cell Lung Cancer: Results from a Large Nationwide Initiative. Journal of Thoracic Oncology. 14(10). S775–S775.
13.
Durgeau, Aurélie, Yasemin Virk, Gwendoline Gros, et al.. (2018). Human preprocalcitonin self-antigen generates TAP-dependent and -independent epitopes triggering optimised T-cell responses toward immune-escaped tumours. Nature Communications. 9(1). 5097–5097.
14.
Mahjoubi, Linda, Franco Cecchi, Christophe Massard, et al.. (2018). Personalized therapy based on sequential molecular analysis leads to 30 months of survival in a patient with diffuse unresectable gastric linitis plastica. Tumori Journal. 104(6). NP38–NP41.
15.
Adam, Julien, Nolwenn Le Stang, Isabelle Rouquette, et al.. (2018). Multicenter harmonization study for PD-L1 IHC testing in non-small-cell lung cancer. Annals of Oncology. 29(4). 953–958.
16.
Fend, Laetitia, Takahiro Yamazaki, Murielle Gantzer, et al.. (2017). Immune Checkpoint Blockade, Immunogenic Chemotherapy or IFN-α Blockade Boost the Local and Abscopal Effects of Oncolytic Virotherapy. Cancer Research. 77(15). 4146–4157.
17.
Eggink, Florine A., Inge C. van Gool, Alexandra Léary, et al.. (2017). Immunological profiling of molecularly classified high-risk endometrial cancers identifies POLE-mutant and microsatellite unstable carcinomas as candidates for checkpoint inhibition. Data Archiving and Networked Services (DANS).
18.
Teuff, Gwénaël Le, J. Guigay, Caroline Caramella, et al.. (2017). Antitumour activity of somatostatin analogues in sporadic, progressive, metastatic pulmonary carcinoids. European Journal of Cancer. 75. 259–267.
19.
Boussemart, Lise, Isabelle Girault, Hélène Malka-Mahieu, et al.. (2016). Secondary Tumors Arising in Patients Undergoing BRAF Inhibitor Therapy Exhibit Increased BRAF–CRAF Heterodimerization. Cancer Research. 76(6). 1476–1484.
20.
Friboulet, Luc, Frédéric Commo, Ken A. Olaussen, et al.. (2011). Molecular Characteristics of ERCC1-Negative versus ERCC1-Positive Tumors in Resected NSCLC. Clinical Cancer Research. 17(17). 5562–5572.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Jennifer H. Yearley Breakdown of academic impact, for papers by Erminia Massarelli Breakdown of academic impact, for papers by Salvador Martín‐Algarra Breakdown of academic impact, for papers by Thomas Olencki Breakdown of academic impact, for papers by Nicolás A. Giraldo Breakdown of academic impact, for papers by Helen K. Angell Breakdown of academic impact, for papers by Takeshi Kuwata Breakdown of academic impact, for papers by Gene Grant Finley Breakdown of academic impact, for papers by Peter Langmuir Breakdown of academic impact, for papers by Ashley Cimino‐Mathews